First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
No initial or ongoing
lab monitoring 1
No tests, including
for TB or baseline
blood panels 1
No need to plan
around live vaccines or
immunization schedules 1
*Amgen, the marketer of Otezla, has entered into a fee-for-service arrangement with CoverMyMeds to provide a more simplified ePA experience after you have chosen to prescribe Otezla. CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved. †The Otezla Co-Pay Card is for eligible commercially insured patients. Terms, conditions, and program maximums apply. Other restrictions may apply. Click here for full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law. Patients who are not eligible can call
1-844-4OTEZLA (1-844-468-3952) to discuss further financial support opportunities. ‡If the patient’s health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla, patients can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 months while pursuing approval from their health plans. No purchase necessary. Click here for full Terms and Conditions.
§The dose of Otezla should be reduced to 30 mg once daily in patients with severe renal impairment (defined as creatinine clearance (CLcr) <30 mL/min estimated by the Cockcroft-Gault equation). For initial dosage titration, it is recommended that Otezla be titrated using only the AM schedule shown here and the PM doses be skipped. From day 6 on, the dose of Otezla is 30 mg once daily. 1
For more information on dosing, click here.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Reference: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.